Oxybutynin
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Oxybutynin: From Overactive Bladder to Restless Legs Syndrome
One-Sentence Summary
Oxybutynin is an antimuscarinic drug originally used to treat overactive bladder, neurogenic bladder and cauda equina syndrome. The TxGNN model predicts it may be effective for restless legs syndrome, but no clinical trials and no publications currently support this prediction, so it is a model-only signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Overactive bladder, neurogenic bladder, cauda equina syndrome (the Singapore licence lists no approved indication text) |
| Predicted New Indication | Restless legs syndrome |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available for this report. Based on known information, oxybutynin is an antimuscarinic agent whose efficacy in overactive bladder is well established. It acts by relaxing the bladder detrusor muscle.
The link to restless legs syndrome is speculative. A possible route is central or peripheral anticholinergic modulation, but nothing in the data compiled for this report supports it. Oxybutynin's anticholinergic burden could even aggravate sleep-related symptoms. The high score of 0.997 comes from a graph-based prediction only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11215P | OBUTIN TABLETS 5 mg (Hanlim Pharmaceutical) | Tablet (oral) | Not stated in the data |
Safety Considerations
- Contraindications (suggested by the knowledge graph, not from label text): The following conditions are linked to oxybutynin as contraindications.
- Eye: angle-closure glaucoma.
- Gastrointestinal: paralytic ileus, intestinal obstruction, toxic megacolon, ulcerative colitis and inflammatory bowel disease, gastroesophageal reflux disease and esophagitis, hiatus hernia.
- Urinary and prostate: bladder neck obstruction, benign prostatic hyperplasia, pyoureter.
- Neuromuscular: myasthenia gravis and other neuromuscular junction diseases.
- Cardiovascular: coronary artery disease, heart conduction disease, sudden cardiac arrest, hypertension.
- Other: hyperthyroidism and Graves disease, kidney disease, liver disease, gallbladder disease.
- Drug Interactions (100 interactions recorded; the first 20 are listed):
- Major: potassium citrate, potassium chloride.
- Moderate: other anticholinergics and antispasmodics (hyoscyamine, atropine, glycopyrronium, clidinium, dicyclomine, trospium, mepenzolate, methscopolamine, propantheline), opioids (morphine, opium), loperamide, eluxadoline, aprepitant, metoclopramide and pramlintide.
Please also refer to the package insert for the official warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a graph-based score, with no trials or literature. The anticholinergic profile of oxybutynin may even worsen sleep-related symptoms.
To proceed, the following is needed:
- Detailed mechanism of action data and a credible biological link to restless legs syndrome
- Systematic literature searches and trial registry checks for this indication
- The Singapore package insert, with its warnings and contraindications, for safety screening
- Review of the anticholinergic burden, especially in older patients
Note on other predicted indications
Other predictions were also reviewed. None is stronger than the leading one as a new use.
| Predicted Indication | TxGNN Score | Evidence Level | Assessment | |------|------|------|------| | Peptic ulcer disease | 99.31% | L4 | Only 1960s descriptive evaluations, plus a 1990 report of oxybutynin-induced reflux esophagitis. Hold. | | Low compliance bladder | 97.88% | L3 | Systematic reviews and cohort studies of intravesical oxybutynin in neurogenic bladder. Closely related to the existing indications, so this is nearly on-label rather than true repurposing. Research Question. | | Attention deficit-hyperactivity disorder | 95.11% | L4 | The literature covers enuresis in children with ADHD, not treatment of ADHD itself. Hold. | | Gastroduodenitis, nephrogenic syndrome of inappropriate antidiuresis, insomnia, faciodigitogenital syndrome, familial episodic pain syndrome, transient tic disorder | 92.4–99.6% | L5 | No supporting evidence. Hold. |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.